Latest News
Feature
Generic clofarabine injection hits the market
The generic is approved for pediatric patients up to 21 years old with relapsed or refractory ALL after two prior regimens.
Conference Coverage
Lung injury risk higher with apheresis blood products
Compared with other red blood cell products, those derived from apheresis significantly increased pulmonary cell interleukin-6 and interleukin-8...
From the Journals
MMR deficiency testing remains low in colorectal cancer patients
Utilization of mismatch repair deficiency testing is poor among patients with colorectal cancer, and remains particularly low among young adults...
From the Journals
TP53 mutations could help stratify MCL patients
The study looks at response to standard-of-care regimens in younger patients.
From the Journals
Lenalidomide shows clinical activity in relapsed/refractory MCL
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
FDA approves letermovir for CMV prophylaxis
The FDA approved the use of letermovir tablets and injections to prevent CMV infection and disease in adults exposed to the virus who have had an...
News
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphoma
Approval was based on a 56% objective response rate for brentuximab vedotin vs. 12% for physician’s choice of methotrexate or bexarotene in a...
News from the FDA/CDC
AML candidate drug back in the pipeline
Phase 1 trials of UCART123 were halted in September but the FDA has given clearance for research to continue, with conditions.
Conference Coverage
Late-Breaking Science preview: Tuesday, Nov. 14
Antithrombotic therapy is the focus of the Late-Breaking Science 5 presentation.
Conference Coverage
Late-Breaking Science preview: Sunday, Nov. 12
AHA’s top abstract picks for Sunday focus on periprocedural dilemmas.
From the Journals
Breast cancer recurrence risk substantial after endocrine treatment
Women who stop adjuvant endocrine therapy after 5 years are still at substantial risk of distant recurrence over the next 15 years, even if their...